Themes · 18 current · 26 dormant
Stock market themes: what moves together
A theme is a group of stocks moving on the same story, such as consumer brands & retail, medtech, diagnostics & life-science tools and AI enterprise software. The research rebuilds its themes every trading day and reads each stock next to the others in its group, because a story that lifts one name usually lifts its neighbours too. Pick a theme you follow to find the stocks in it and their research. Every count on this page is the number of stocks whose research note is tagged with the theme; one stock can carry more than one. 636 stocks are in a current theme.
More ways in
Stocks per theme · all 18 current themes
- Consumer brands & retail89
- Medtech, diagnostics & life-science tools81
- AI enterprise software78
- M&A & special situations78
- Oncology & immunology58
- Cyclical industrials44
- Fintech, payments & credit43
- Defense & aerospace32
- Banks, insurers & capital markets30
- Rare disease & gene therapy30
- Managed care & health services27
- Travel & leisure26
- Cybersecurity21
- Ad tech & digital advertising18
- Solar & clean energy9
- Cardiovascular therapeutics7
- GLP-1 & obesity drugs6
- Streaming, media & entertainment5
Themes that overlap · stocks in both
44 stocks carry two or more current themes. The pairs that share the most:
- M&A & special situationsMedtech, diagnostics & life-science tools5
- AI enterprise softwareCybersecurity4
- Fintech, payments & creditM&A & special situations3
- M&A & special situationsOncology & immunology3
- Medtech, diagnostics & life-science toolsOncology & immunology3
- Ad tech & digital advertisingAI enterprise software2
- AI enterprise softwareM&A & special situations2
- Cardiovascular therapeuticsRare disease & gene therapy2
Consumer brands & retail
89 stocksStage: maturing, as of 15 November 2026.
Grouped on the 13 November 2026 close
PTLOPortillo'sMedium Portillo's turned same-restaurant sales positive and raised adjusted EBITDA guidance to $98–$101 million on 5 November 2026, leaving the shares modestly likelier than not to beat the S&P 500. Transactions still fell 0.7%, so the January…ARHSArhausMedium Arhaus's furniture orders are running far ahead of deliveries, giving the shares a modest edge over the S&P 500: Q3 2026 comparable written sales rose 13.9% and client deposits reached $325.0 million. The Q4 2026 report, expected in late…BOBSBobs Discount FurnitureLow Bob's Discount Furniture shares look more likely to lag the S&P 500 as a diesel-driven gross margin cut and a 30% furniture tariff from 1 January 2027 weigh on a stock already near analyst targets. The fourth-quarter report settles whether…REALRealRealMedium The RealReal's 29 October 2026 beat and raise, with luxury-resale GMV up 23%, makes the shares modestly likely to beat the S&P 500; the fourth-quarter report must deliver the guided $27.5–29.0 million of adjusted EBITDA.CPRICapri HoldingsMedium Capri Holdings' Michael Kors turnaround gives the shares a modest edge over the S&P 500 after the 30 October 2026 beat-and-raise, despite a CEO handover on 4 January 2027. The fiscal third-quarter report, expected in early February 2027,…
Tagged on earlier closes
CHAChagee HoldingsMedium Chagee Holdings is modestly more likely to lead the S&P 500 over three months: its shares cleared $14.00 on a $1.95 special dividend. The third-quarter report, expected around 27 November 2026, shows whether China same-store sales, down…COSTCostco WholesaleMedium Costco Wholesale's underlying sales growth held at 7.3% in October and a $30 special dividend followed on 10 November 2026, giving the shares a modest edge over the S&P 500. The November sales report (~2 December 2026) and first-quarter…CROXCrocsMedium Crocs, Inc. is more likely to lead the S&P 500 over three months: a third-quarter beat and a third guidance raise lifted full-year adjusted EPS to $14.45–$14.65, and the fourth-quarter report due around mid-February 2027 settles it.CRSRCorsair GamingMedium Corsair Gaming's recovery case holds after it beat third-quarter guidance and raised its 2026 outlook on 5 November 2026; the fourth-quarter report shows whether profit holds as memory gross margin falls to 18%–20%.
Medtech, diagnostics & life-science tools
81 stocksStage: maturing, as of 15 November 2026.
Grouped on the 13 November 2026 close
ENOVEnovisMedium Enovis Corporation's orthopedic turnaround passed its 5 November 2026 test with 4.6% organic growth, raised earnings guidance and a $200 million buyback. The late-February 2027 full-year report shows whether about 5% growth and at least…KIDSOrthoPediatricsLow OrthoPediatrics shares are more likely to lag the S&P 500 because the $33.67 close on 11 November 2026 sits above six of seven post-report analyst targets despite 19% sales growth. Preliminary fourth-quarter revenue, expected about…AXGNAxogenMedium Axogen's nerve-repair revenue grew 26.2% last quarter and a $754 million prostate market sits outside guidance, giving the shares a modest edge over the S&P 500; the Q4 2026 report settles whether revenue excluding BioCircuit reaches the…GKOSGlaukosMedium Glaukos's iDose TR glaucoma implant and Epioxa keratoconus therapy lifted third-quarter 2026 sales 58% to $211.0 million, giving the shares a modest edge on a $1 billion 2027 outlook. Medicare's pending iDose TR coverage decision and…VCELVericelMedium Vericel's knee-cartilage implant MACI is growing above 20% a year and the 5 November 2026 report raised 2026 revenue guidance to $344–346 million. The fourth-quarter report settles the case by showing whether MACI reaches about $102…
Tagged on earlier closes
AZTAAzentaHigh Azenta is more likely to beat the S&P 500 over three months because its fiscal 2027 plan, issued 10 November 2026, adds 3% to 5% organic growth and a wider margin. The fiscal first-quarter report, expected around early February 2027, shows…ADPTAdaptive BiotechnologiesMedium Adaptive Biotechnologies is more likely than not to beat the S&P 500 over three months because clonoSEQ tests rose 46% in the third quarter of 2026 and MRD revenue guidance rose to $276–286 million. Medicare's final 2027 lab rates,…AVTRAvantorMedium Avantor's lab-supply volumes are growing again, with Q3 2026 organic growth of 5.2% and a raised FY2026 outlook, but distribution margins fell. The 8 December 2026 Investor Day shows whether margin targets support further gains in the…CDNACareDxMedium CareDx's shares are modestly more likely than not to beat the S&P 500: transplant testing revenue grew 39% in the third quarter excluding catch-up collections and 2026 guidance rose to $520–530 million. CMS's final 2027 Medicare rates, due…
AI enterprise software
78 stocksStage: maturing, as of 15 November 2026.
Grouped on the 13 November 2026 close
TLSTelosMedium Telos Corporation's third-quarter beat and raised 2026 outlook, led by Telos ID and TSA PreCheck volumes, make the shares modestly more likely than not to beat the S&P 500. The first 2027 outlook, expected in early 2027, shows whether…CLVTClarivateLow Clarivate's shares are more likely to lag the S&P 500 over the next three months: the $533 million debt tender that settled on 13 November 2026 is priced in, and 1.3% organic recurring growth is too slow to lift the stock before the 2027…GDYNGrid Dynamics HoldingsMedium Grid Dynamics' AI work is lifting the IT-services firm back toward double-digit growth at margins near 20%, which favors the shares beating the S&P 500. The Q4 2026 report, expected around late February 2027, shows whether 2027 guidance…VYXNCR VoyixMedium NCR Voyix's shares have a modest edge over the S&P 500 because large grocers and restaurant chains are signing onto its cloud platform and its margins are rising. The fourth-quarter report, expected in February 2027, shows whether 2026…AEYEAudioEyeLow AudioEye's shares are more likely to lag the S&P 500: the company is profitable, but sales grew 7%, the executive chairman kept selling, and the stock is up 137% in three months; the Q4 report decides it.
Tagged on earlier closes
APPNAppianMedium Appian's third-quarter 2026 revenue rose 25% to $234.6 million and full-year guidance went up again, giving the shares a modest edge over the S&P 500; the fourth-quarter report, expected around 18 February 2027, shows whether cloud…MSFTMicrosoftMedium Microsoft's shares are modestly more likely to lead the S&P 500 over three months because Azure grew 48% in the September quarter and is guided to 49–50% for December. The fiscal second-quarter report, expected in late January 2027, shows…ZETAZeta Global HoldingsMedium Zeta Global's shares hold a modest edge over the S&P 500 after the company beat its third-quarter guide and raised 2026 revenue guidance to $1.853 billion–$1.857 billion on 9 November 2026; the fourth-quarter report, expected in February…EPAMEPAM SystemsMedium EPAM Systems is modestly more likely than not to beat the S&P 500 as its $1.8 billion buyback, including a $500 million UBS repurchase signed 9 November 2026, shrinks the share count; the February 2027 outlook shows whether organic growth…
M&A & special situations
78 stocksStage: maturing, as of 15 November 2026.
Grouped on the 13 November 2026 close
ULBIUltralifeLow Ultralife Corporation trades as a capped claim on EnerSys's $16.00-per-share cash offer, so it is more likely to lag the S&P 500 than lead it; US and UK clearances and the tender, first due to expire on 3 December 2026, settle whether…SLNSilence TherapeuticsLow Silence Therapeutics' shares trade just under Merck KGaA's $20-per-ADS cash takeover price, so they are more likely to lag the S&P 500 than lead it over three months. The proxy statement that dates the scheme vote, and antitrust clearance…SGRYSurgery PartnersLow Surgery Partners' shares, at $26.58 on 12 November 2026, already price in more than HealthSpan Partners' $25.00 cash deal pays and are more likely to lag the S&P 500. Whether the rejected $28.00 bidder, reported to be UnitedHealth, returns…BRZEBrazeLow Salesforce's agreed $47.50-per-share cash takeover of Braze caps the shares just under the offer, so they are more likely to lag the S&P 500 than lead it over three months. The US antitrust review, the stockholder vote or a rival bid…EVGOMedium EVgo's shares track majority owner LS Power's $2.00-per-share cash take-private offer and closed at $1.75 on 12 November 2026, below it. The special committee's answer settles the case: a signed deal at $2.00 closes the gap, while a…
Tagged on earlier closes
UUnity SoftwareMedium Unity Software's advertising turnaround and reported takeover interest make the shares modestly more likely than not to beat the S&P 500 over three months; the fourth-quarter 2026 report, expected around 11 February 2027, settles whether…CVSCVS HealthMedium CVS Health is modestly more likely to beat the S&P 500 over three months: Aetna's costs improved and 2026 guidance rose, and the February 2027 report tests the 2027 outlook of at least $8.65 per share.GPNGlobal PaymentsMedium Global Payments trades on a reported $40 billion CD&R and GTCR buyout, and nine brokers raised targets after in-line third-quarter results on 5 November 2026; a signed deal at a premium, or word that talks have ended, settles the case.MBGLMobility GlobalMedium Mobility Global, the CARFAX owner spun off from S&P Global, is more likely to beat the S&P 500 over three months because its third-quarter organic growth sped up to 7.6% and a $350–450 million buyback is due to start before the end of…
Oncology & immunology
58 stocksStage: maturing, as of 15 November 2026.
Grouped on the 13 November 2026 close
XNCRXencorMedium Xencor's shares hold a modest edge over the S&P 500 on XmAb819's 45.5% confirmed response rate in advanced kidney cancer and cash funding into 2029. First-half 2027 data in at least 20 patients at 400 mcg/kg and the FDA's view on…DCTHDelcath SystemsMedium Delcath Systems' shares are more likely than not to beat the S&P 500 after third-quarter revenue of $35.1 million lifted 2026 guidance to $115–117 million on 9 November 2026; the full-year report, expected around March 2027, shows whether…REPLReplimune GroupMedium Replimune's melanoma drug TUDRIQEV, first delivered on 6 October 2026, gives the shares a modest edge over the S&P 500 as early prescribing builds. The fiscal third-quarter report, expected around February 2027, carries the first sales…NBTXNanobiotixLow Nanobiotix shares are more likely to lag the S&P 500 over the next three months because the Phase 3 NANORAY-312 head and neck cancer readout that decides the case has no date. Cash runs into 2029, so news on that trial's timing or result…GMABGenmab A/SMedium Genmab's own cancer drugs are becoming a second engine beside its DARZALEX royalty, with three launches targeted for 2027. ASH data on 14 December 2026 and the 16 December 2026 R&D update show whether filings stay on track.ORKAOruka TherapeuticsMedium Oruka Therapeutics is modestly more likely to beat the S&P 500 over three months: its psoriasis antibody ORKA-001 cleared skin completely in 61% of high-dose patients against 0% on placebo, and the December 2026 52-week EVERLAST-A data…
Tagged on earlier closes
ABBVAbbVieMedium AbbVie's Skyrizi and Rinvoq, each up more than 22% in the 30 October 2026 third-quarter report, keep lifting guidance and analyst targets, so the shares modestly favour beating the S&P 500. The fourth-quarter report expected around 29…AMGNAmgenMedium Amgen is modestly more likely than not to beat the S&P 500 over three months because Repatha, Evenity and newer drugs are outgrowing biosimilar losses. The fourth-quarter report and 2027 outlook, expected in early February 2027, settle it.MRKMerckMedium Merck's newer drugs and under-the-skin Keytruda are carrying its growth after raised 2026 guidance on 29 October 2026; the early-February 2027 outlook shows whether moderate growth absorbs over $2 billion of generic losses.
Cyclical industrials
44 stocksStage: maturing, as of 15 November 2026.
Grouped on the 13 November 2026 close
CMCOColumbus McKinnonMedium Columbus McKinnon's Kito Crosby merger is beating profit forecasts and its chief executive bought shares after the 3 November 2026 guidance raise; the fiscal third-quarter report, expected in early February 2027, must show leverage falling…HRIHerc HoldingsLow Herc Holdings looks more likely to lag the S&P 500 over three months because its raised 2026 guide is largely priced in after shares rebounded to $173.90 on 11 November 2026 without new company news. The fourth-quarter report, expected…TBITrueblueMedium TrueBlue's staffing recovery is in reported results (third-quarter revenue $520.7 million, fourth-quarter outlook $499–519 million), so the shares are more likely to lead the S&P 500 over three months; the late-February 2027 report tests…HAYWHayward HoldingsLow Hayward Holdings' raised 2026 guidance is already priced into shares trading above most broker targets, so they are more likely to lag the S&P 500; the late-February 2027 fourth-quarter report shows whether early-buy orders become sales.ONTOnterrisMedium Onterris's shares trade on a board-led strategic review that has engaged outside buyers and on a third-quarter cash flow recovery; a review outcome and fourth-quarter operating cash flow against the $30.0M–$40.0M guide settle the case.
Tagged on earlier closes
APOGApogee EnterprisesMedium Apogee Enterprises' shares are modestly more likely to beat the S&P 500 because pricing and cost gains lifted fiscal 2027 adjusted EPS guidance to $3.00–$3.40 on 6 October 2026. The report expected around 6 January 2027 shows whether those…GICGlobal IndustrialMedium Global Industrial Company's sales strategy is delivering high-single-digit daily sales growth and wider operating margins even without tariff refunds. The fourth-quarter report, expected around late February 2027, settles whether that…MTWManitowocMedium Manitowoc's crane orders and raised 2026 guidance give the shares a modest edge over the S&P 500; the fourth-quarter report, expected around February 2027, settles whether about $90 million of fourth-quarter free cash flow arrives.REZIResideo TechnologiesMedium Resideo Technologies is modestly more likely than not to beat the S&P 500 after a third-quarter beat in its first full quarter as a standalone controls maker. The fourth-quarter report expected in February 2027 shows whether its 6% core…
Fintech, payments & credit
43 stocksStage: saturated, as of 15 November 2026.
Grouped on the 13 November 2026 close
UPBDUpbound GroupMedium Upbound Group's tighter Acima lending is lifting profit and cash flow as lease volume shrinks, Brigit adds growth, and executives kept buying stock; the late-February 2027 Q4 report shows whether Acima volume levels off as guided.TREELendingTreeMedium LendingTree's insurance-led growth, falling debt and first planned buyback since 2022 give its shares a modest edge over the S&P 500 even after they gave back part of the post-report rally. The fourth-quarter report settles whether the…FISVFiservMedium Fiserv's revenue decline has levelled off and management is cutting costs and selling or shutting weak units; the fourth-quarter report, expected around February 2027, settles whether Merchant Solutions returns to its guided 6% to 8%…CHYMChime FinancialMedium Chime Financial's revenue growth sped up to 32% and its 2026 outlook rose a third time, giving the shares a modest edge over the S&P 500 over three months; the fourth-quarter 2026 report, against a $757–767 million forecast, settles it.
Tagged on earlier closes
CVNACarvanaMedium Carvana is taking share in a flat used-car market, with third-quarter retail units up 39% and more units guided for the fourth quarter. The February 2027 report shows whether volume growth outruns falling profit per car.EVEREverQuoteMedium EverQuote's third-quarter revenue of $218.1 million and adjusted EBITDA of $35.5 million beat the top of its guidance, giving the shares a modest edge over the S&P 500; the fourth-quarter report shows whether profit holds within a lower…GENGen DigitalMedium Gen Digital's raised fiscal 2027 outlook and its step back from a large GoDaddy deal give the shares a modest edge over the S&P 500; the Q3 FY27 report in early 2027 tests the $5.465–5.515 billion revenue range.GPNGlobal PaymentsMedium Global Payments trades on a reported $40 billion CD&R and GTCR buyout, and nine brokers raised targets after in-line third-quarter results on 5 November 2026; a signed deal at a premium, or word that talks have ended, settles the case.INTUIntuitMedium Intuit's shares hold a modest edge over the S&P 500 as AI agents, Credit Karma Tax and the Sequence deal target price-driven customer losses; the 19 November 2026 fiscal Q1 report settles it against the $4.294–$4.313 billion revenue guide.
Defense & aerospace
32 stocksStage: maturing, as of 15 November 2026.
Grouped on the 13 November 2026 close
FLYFirefly AerospaceMedium Firefly Aerospace's third-quarter beat, raised revenue floor and record $1.7 billion backlog make its shares modestly likely to beat the S&P 500; the fourth-quarter Alpha Block II debut settles whether launches carry the $440–450 million…SAROStandardAeroMedium StandardAero's engine-overhaul profits are growing faster than revenue: third-quarter 2026 adjusted EBITDA rose 15% and the company raised 2026 guidance again on 5 November 2026. The fourth-quarter report, expected around 26 February 2027,…
Tagged on earlier closes
ARXSArxisMedium Arxis, a defense, space and industrial component roll-up, is modestly likely to beat the S&P 500 after 29% organic growth and a raised outlook on 28 October 2026. Its fourth-quarter report, due about late February 2027, tests whether…AVEXAEVEXMedium AEVEX's core drone and maritime business is outgrowing its fading Ukraine work, making the shares modestly likely to beat the S&P 500 over three months. First orders under its nearly $400 million drone contract and the 2027 outlook at the…CDRECadre HoldingsMedium Cadre Holdings' 30% third-quarter sales jump to $202.9 million, 10% organic growth and first $100 million buyback give the shares a modest edge over the S&P 500. The early-March 2027 fourth-quarter report settles whether sales hold near…KRMNKarman HoldingsMedium Karman Space & Defense's 66% revenue growth and $1.7 billion backlog make its shares, 66% below their January high, more likely than not to beat the S&P 500. The fourth-quarter report and 2027 outlook, expected around March 2027, settle…LMTLockheed MartinMedium Lockheed Martin's record $292.0 billion backlog and raised 2026 guidance make the shares modestly more likely than not to beat the S&P 500 after their post-midterm rebound. The 11 December 2026 federal funding deadline shows whether…RKLBRocket LabMedium Rocket Lab's record third-quarter revenue of $267.8 million and its $3.57 billion backlog give the shares a modestly better-than-even case against the S&P 500 over three months. A dated Neutron launch quarter and fourth-quarter revenue…RTXMedium RTX Corporation's record $340 billion backlog and raised 2026 guidance outweigh a defense budget now likely to slip into 2027; the 11 December 2026 funding deadline and the first 2027 guidance at the late-January report settle the case.
Banks, insurers & capital markets
30 stocksTracked as of 11 November 2026.
PLMRPalomar HoldingsMedium Palomar Holdings is more likely than not to beat the S&P 500 over three months because estimates keep rising after its fourth 2026 guidance raise, to $280–285 million of adjusted net income. The fourth-quarter report, expected around…AAMIAcadian Asset ManagementMedium Acadian Asset Management's eleven straight quarters of client inflows, record fees and resumed buybacks give its shares a modest edge over the S&P 500. The fourth-quarter report, expected in late January 2027, shows whether flows stay…CCitigroupMedium Citigroup is modestly more likely to beat the S&P 500 over three months: its returns beat its 11% target while the shares fell 10.5% on market-wide selling. The mid-January 2027 fourth-quarter report shows whether returns and buybacks hold.HIPOHippo HoldingsMedium Hippo Holdings has modestly better-than-even odds of beating the S&P 500 after it raised 2026 profit guidance on 29 October 2026 on a falling expense ratio. Fourth-quarter underwriting against its 97–98% combined ratio guidance settles the…MSMorgan StanleyMedium Morgan Stanley's shares have modestly better than even odds of beating the S&P 500, carried by its co-lead role on Anthropic's IPO and record wealth flows. The IPO pricing, reported for 18 November 2026, and the fourth-quarter report,…PRCHPorch GroupMedium Porch Group's insurance fees beat in Q3 2026 and lifted 2026 adjusted EBITDA guidance to $135-140M, and the shares hit a 52-week high on 10 November 2026 despite CEO stock sales. Year-end Reciprocal surplus and the Q4 report around…SLDESlide Insurance HoldingsMedium Slide Insurance is earning well ahead of plan on Florida homeowners policies and paying a $1.50 special dividend after raising 2026 net income guidance to $500–520 million. The fourth-quarter report, estimated around 25 February 2027,…TWTradeweb MarketsMedium Tradeweb Markets' 26.3% October volume growth points to fourth-quarter revenue growth above the third quarter's 14.9%. The November volume report around 4 December 2026 and fourth-quarter results show whether revenue keeps pace as credit…BACBank of AmericaLow Bank of America's shares look more likely to lag the S&P 500 as weak fees and trading, a $1.2 billion penalty and falling broker targets outweigh 8% lending-income growth; the 15 January 2027 fourth-quarter report shows whether fees…
Rare disease & gene therapy
30 stocksStage: accelerating, as of 15 November 2026.
Grouped on the 13 November 2026 close
VRDNViridian TherapeuticsMedium Viridian Therapeutics' shares are modestly more likely than not to beat the S&P 500: Lumvoa's $24.7 million first full quarter beat estimates and VRDN-008 data on 9 November 2026 added an autoimmune program. Fourth-quarter Lumvoa sales,…XERSXeris Biopharma HoldingsMedium Xeris Biopharma's shares are modestly more likely than not to beat the S&P 500 over three months because Recorlev sales rose 93% to $71.5 million in the third quarter and 2026 revenue guidance rose to $395–405 million. Preliminary…IRONDisc MedicineMedium Disc Medicine's shares are modestly favoured to beat the S&P 500 over three months because bitopertin passed its Phase 3 APOLLO trial on 19 October 2026, answering the FDA's February rejection. ASH pipeline data from 12 December 2026 and…LQDALiquidiaMedium Liquidia Corporation's shares are modestly more likely to beat the S&P 500 because YUTREPIA sales rose 31% to $222.7 million in the third quarter with record October shipments; preliminary fourth-quarter sales, due in early January 2027,…ETONEton PharmaceuticalsMedium Eton Pharmaceuticals is modestly more likely than not to beat the S&P 500 over three months, after third-quarter revenue of $57.9 million, up 158%, lifted its 2026 guide above $175 million. The fourth-quarter report, expected around…
Tagged on earlier closes
COAGHemab Therapeutics HoldingsMedium Hemab Therapeutics is modestly more likely than not to beat the S&P 500 over three months: its pivotal sutacimig trial has started and cash is guided into 2029. Updated Factor VII deficiency data at the ASH meeting on 14 December 2026 test…CYRXCryoPortMedium Cryoport's cold-chain business for cell and gene therapies is growing faster and posted a second positive adjusted EBITDA quarter, with 2026 revenue guidance raised to $197–199 million. The fourth-quarter report settles whether that pace…PVLAPalvella TherapeuticsMedium Palvella Therapeutics has pulled back from its record close while the FDA reviews QTORIN rapamycin for a 28 February 2027 decision, with no adverse review news and $236.7 million in cash; review updates and the fourth-quarter Phase 3 start…CAPRCapricor TherapeuticsLow Capricor Therapeutics' shares are more likely to lag the S&P 500 because deramiocel's approval faces an FDA panel that voted 9-3 against its evidence in July 2026. The FDA's action on the narrowed application, due by 22 November 2026,…
Managed care & health services
27 stocksStage: maturing, as of 15 November 2026.
Grouped on the 13 November 2026 close
ARDTArdent HealthMedium Ardent Health's cost-led hospital turnaround is running ahead of plan, with 2026 adjusted EBITDA guidance raised to $500–$535 million and Guggenheim and Stephens targets at $21; the 2027 outlook due with year-end results settles whether…TDOCTeladoc HealthMedium Teladoc Health's Q3 2026 beat and fast-growing BetterHelp insurance revenue give the shares a modest edge over the S&P 500. The refinancing of $1.0 billion of notes due June 2027 and the Q4 report settle whether the turnaround holds.
Tagged on earlier closes
AGLagilon healthMedium agilon health roughly doubled its 2026 adjusted EBITDA guidance to $145–$155 million after a second profitable quarter, giving the shares a modest edge over the S&P 500; the 17 November 2026 investor event and the Q4 report show whether…BTSGBrightSpring Health ServicesMedium BrightSpring Health Services is growing profit faster than revenue, with third-quarter 2026 adjusted EBITDA up 42% on specialty pharmacy margins and acquired home-health branches. Its first 2027 guidance, expected around late February…CVSCVS HealthMedium CVS Health is modestly more likely to beat the S&P 500 over three months: Aetna's costs improved and 2026 guidance rose, and the February 2027 report tests the 2027 outlook of at least $8.65 per share.EVHEvolent HealthMedium Evolent Health's margin repair now has evidence: Q3 medical costs fell to 93.0% of revenue and 2026 adjusted EBITDA guidance rose to $130–135 million. The late-February Q4 report, with its 2027 range, decides whether the $150 million-plus…HNGEHinge HealthMedium Hinge Health's shares can lead the S&P 500 on 52% revenue growth and a raised $879–881 million 2026 guide; the February 2027 report must show fourth-quarter revenue of at least $249 million to keep the case.HUMHumanaMedium Humana's third-quarter cost beat and higher $9.50 adjusted EPS floor, reported 6 November 2026, make its shares modestly more likely than not to beat the S&P 500 as the Star Ratings recovery lifts 2028 margins. The 10 December investor…LHLabcorp HoldingsMedium Labcorp's 11.5% Central Labs growth and raised 2026 guidance make its shares modestly more likely to beat the S&P 500 over three months. Final 2027 Medicare lab rates, due from CMS in late November 2026, test the case, and the February…
Travel & leisure
26 stocksStage: maturing, as of 15 November 2026.
Grouped on the 13 November 2026 close
Tagged on earlier closes
ALGTAllegiant TravelMedium Allegiant Travel Company is modestly more likely to beat the S&P 500 over three months as fares outrun fuel; its 7 December 2026 investor day shows whether 2027 targets back the above-$6.00 2026 earnings guide.CHDNChurchill DownsMedium Churchill Downs' growing Kentucky machine profit, record third quarter and $750 million buyback outweigh its shrinking Virginia machine revenue; monthly state figures and the fourth-quarter report expected around 25 February 2027 decide…INNSummit Hotel PropertiesMedium Summit Hotel Properties looks modestly more likely than not to beat the S&P 500: it raised 2026 guidance again on 3 November 2026 and October RevPAR rose about 5.5%. The late-February 2027 report shows whether fourth-quarter growth held…LINDLindblad Expeditions HoldingsMedium Lindblad Expeditions' shares are modestly more likely than not to beat the S&P 500 as 91% occupancy, 6% higher pricing and record 2027 bookings lift profit. The fourth-quarter report and 2027 outlook, expected around late February 2027,…RCLRoyal Caribbean GroupMedium Royal Caribbean Group's third-quarter beat, raised 2026 outlook and rising analyst targets give the shares a modestly better-than-even chance of beating the S&P 500, despite heavy director selling in November 2026. The fourth-quarter…AALAmerican Airlines GroupLow American Airlines shares are more likely to lag the S&P 500 over three months because jet fuel near $4.70 a gallon is consuming record revenue; the fourth-quarter report, expected in late January 2027, shows whether the guided loss of…DISWalt DisneyLow The Walt Disney Company's shares look more likely to trail the S&P 500 than lead it, because a 14.2% three-month gain already prices in parks, streaming and cost-cut gains. The 17 November 2026 fiscal Q4 report shows whether fiscal 2027…OSWOneSpaWorld HoldingsLow OneSpaWorld, the spa operator on most large cruise ships, raised 2026 guidance but its shares already trade near analysts' targets and are more likely to lag the S&P 500; Carnival's December outlook and the late-February report decide it.
Cybersecurity
21 stocksStage: saturated.
GENGen DigitalMedium Gen Digital's raised fiscal 2027 outlook and its step back from a large GoDaddy deal give the shares a modest edge over the S&P 500; the Q3 FY27 report in early 2027 tests the $5.465–5.515 billion revenue range.NTSKNetskopeMedium Netskope's 29% revenue growth and raised fiscal 2027 outlook make the shares modestly more likely than not to beat the S&P 500, with RBC and Mizuho lifting targets in November. The 2 December 2026 fiscal Q3 report settles it: revenue must…CRWDCrowdStrike HoldingsLow CrowdStrike's shares are more likely to lag the S&P 500 over the next three months because at about 156 times forward earnings they already price in fast growth. The 1 December 2026 report settles it by showing whether net new annual…OSPNOneSpanLow OneSpan's move from hardware tokens to subscription software is working, but its guidance implies a slower fourth quarter after a 32.1% three-month rise, so the shares are more likely to lag the S&P 500. The report expected in late…PANWPalo Alto NetworksLow Palo Alto Networks shares are more likely to lag the S&P 500 until AI security demand lifts its $14.10B–$14.20B fiscal 2027 revenue outlook; the 18 November 2026 fiscal Q1 report settles it. Jefferies cut its target to $400 from $450 on 12…RPDRapid7Low Rapid7's shares look more likely to lag the S&P 500: cost cuts drove a third-quarter profit beat on 4 November 2026, but the company guides recurring revenue lower again for the fourth quarter. The February 2027 report and first 2027…TENBTenable HoldingsLow Tenable's revenue growth is guided to slow to about 6.9% in the fourth quarter from 9.5%, so its shares are more likely to trail the S&P 500 than lead it; the February 2027 report and first 2027 outlook show whether the Tenable One…ATENA10 NetworksMedium A10 Networks' third-quarter revenue rose 22.6% to $91.5 million and full-year growth guidance went to about 16%, which moves the case from unproven to supported; the shares still trade below the $30 June breakout level.FROGJFrogMedium JFrog's third-quarter beat and second full-year raise, with cloud revenue up 60%, support the shares leading the S&P 500. The fourth-quarter report, due around February 2027, tests whether revenue meets the $183M-$185M guide.
Ad tech & digital advertising
18 stocksStage: saturated, as of 15 November 2026.
Grouped on the 13 November 2026 close
APPAppLovinMedium AppLovin's third-quarter 2026 revenue rose 55% to $2.185 billion and put growth back on track. The fourth-quarter report, expected around February 2027, shows whether its partly rolled-out ad models hold growth above the guided 43–44%.ZETAZeta Global HoldingsMedium Zeta Global's shares hold a modest edge over the S&P 500 after the company beat its third-quarter guide and raised 2026 revenue guidance to $1.853 billion–$1.857 billion on 9 November 2026; the fourth-quarter report, expected in February…EVCEntravision CommunicationMedium Entravision's ad-technology unit grew 133% in the third quarter, beating its own guide, and the shares have held the gain; the fourth-quarter report in early 2027 settles whether ATS growth stays above 100%.
Tagged on earlier closes
QNSTQuinStreetMedium QuinStreet's shares are more likely than not to beat the S&P 500 over three months after it beat guidance and raised its fiscal 2027 outlook on 4 November 2026; the early-February 2027 report shows whether insurance-carrier ad spending…UUnity SoftwareMedium Unity Software's advertising turnaround and reported takeover interest make the shares modestly more likely than not to beat the S&P 500 over three months; the fourth-quarter 2026 report, expected around 11 February 2027, settles whether…MGNIMagniteMedium Magnite's connected-TV growth beat guidance by a wide margin and lifted its 2026 outlook, giving the shares a modest edge over the S&P 500. The fourth-quarter report, estimated for late February 2027, shows whether growth holds once…PUBMPubMaticMedium PubMatic's Q3 2026 beat, with revenue up 17% to $79.6 million and connected TV growth above 30%, supports a revenue recovery the shares have nearly priced back to their 52-week high; Q4 revenue of at least the $91 million guidance floor…STGWStagwellMedium Stagwell's technology and data units are lifting profit faster than revenue, with third-quarter adjusted EBITDA up 25% on 10% revenue growth, giving the shares a modest edge. The February 2027 guidance, the first without election spending,…BIDUBaiduLow Baidu's shrinking search advertising still outweighs its fast-growing AI cloud, so the ADS is more likely to lag the S&P 500 over three months; the third-quarter report on 16 November 2026 shows whether the advertising decline narrows.
Solar & clean energy
9 stocksStage: saturated, as of 15 November 2026.
Grouped on the 13 November 2026 close
CHPTChargePoint HoldingsLow ChargePoint shares are more likely to lag the S&P 500 after a 102% three-month rally that outran a business guiding third-quarter revenue below its second quarter. ChargePoint's early-December third-quarter report shows whether revenue and…ARRYArray TechnologiesLow Array Technologies' shares are more likely to lag the S&P 500 while they trade on the all-stock Shoals merger after a cut to 2026 guidance; the S-4 filing, both shareholder votes and a first-quarter-2027 closing decide whether the $2.2–2.4…
Tagged on earlier closes
FRVOFervo EnergyLow Fervo Energy shares look more likely to lag the S&P 500 over three months: IPO lock-up supply and broker target cuts outweigh an $11.9 billion backlog. Cape Station's GeoBlocks 2 and 3 reaching commercial operation by 1 January 2027 decide…TET1 EnergyLow T1 Energy's shares are more likely to lag the S&P 500 over three months because its G2_Austin cell plant still lacks closed financing and unrestricted cash was $59.5 million at 30 September 2026; a financing close, targeted by year-end…NXTNextpowerMedium Nextpower beat and raised fiscal 2027 guidance to $4.2B–$4.45B revenue on 28 October 2026, and the shares closed at $104.89 on 9 November 2026; the 16 November 2026 Capital Markets Day shows whether the longer-term outlook supports the…CSIQCanadian SolarLow Canadian Solar's shares are more likely to lag the S&P 500 over three months: subsidiary CSI Solar's revenue fell 42.63% in the third quarter, and the parent's own third-quarter report, expected around 18 November 2026, must show a turn to…ENPHEnphase EnergyLow Enphase Energy's core residential business is shrinking faster than its transformer pivot can offset, so the shares are more likely to lag the S&P 500; the fourth-quarter 2026 report, guided at $225–255 million, settles it.FSLRFirst SolarLow First Solar's third-quarter report cut 2026 sales guidance, left backlog at 44.0 GW and showed new US bookings near $0.36 per watt, so the case now rests on the $0.38 import price floor starting 4 December 2026 lifting prices.SHLSShoals Technologies GroupLow Shoals Technologies' third-quarter beat and raised 2026 revenue guide are now overshadowed by its 4 November 2026 all-stock merger with ARRAY Technologies, which makes the shares a claim on the combined company; shareholder votes and a Q1…
Cardiovascular therapeutics
7 stocksTracked as of 11 November 2026.
KNSAKiniksa Pharmaceuticals InternationalMedium Kiniksa Pharmaceuticals is modestly more likely than not to beat the S&P 500 over three months on its third 2026 ARCALYST guidance raise, to $1.045–1.050 billion. Fourth-quarter sales and the first 2027 range, due in the early-2027 results…AMGNAmgenMedium Amgen is modestly more likely than not to beat the S&P 500 over three months because Repatha, Evenity and newer drugs are outgrowing biosimilar losses. The fourth-quarter report and 2027 outlook, expected in early February 2027, settle it.LQDALiquidiaMedium Liquidia Corporation's shares are modestly more likely to beat the S&P 500 because YUTREPIA sales rose 31% to $222.7 million in the third quarter with record October shipments; preliminary fourth-quarter sales, due in early January 2027,…CRSPCRISPR TherapeuticsLow CRISPR Therapeutics shares are more likely to lag the S&P 500 over three months: they hit a 52-week closing low of $42.62 on 12 November 2026 despite strong CTX310 data, and December's zugo-cel data at ASH is the next test.EWTXEdgewise TherapeuticsMedium Edgewise Therapeutics is modestly more likely than not to beat the S&P 500 over three months: FDA-cleared Phase 3 plans for heart drug EDG-7500, $1.74 billion of cash and unconfirmed takeover reports support it. The STRATUS-HCM trial…CRDLCardiol TherapeuticsLow Cardiol Therapeutics is more likely to lag the S&P 500 over three months: the MAVERIC Phase III topline is guided for mid-2027, and the company has begun selling stock under a US$75 million at-the-market program. That readout settles the…IKTInhibikase TherapeuticsLow Inhibikase Therapeutics' IKT-001 for pulmonary arterial hypertension is funded, with $193.3M cash on 30 September 2026, but dilution and warrant-dependent runway weigh on shares at $1.55; 2027 interim safety data is next.
GLP-1 & obesity drugs
6 stocksTracked as of 11 November 2026.
LLYEli LillyMedium Eli Lilly's shares are more likely than not to beat the S&P 500 over three months, as tirzepatide volume still outruns price cuts and Foundayo won China approval on 12 November 2026. The fourth-quarter report and 2027 outlook, expected…AMGNAmgenMedium Amgen is modestly more likely than not to beat the S&P 500 over three months because Repatha, Evenity and newer drugs are outgrowing biosimilar losses. The fourth-quarter report and 2027 outlook, expected in early February 2027, settle it.HIMSHims & Hers HealthLow Hims & Hers Health shares are more likely to lag the S&P 500 after a 9 November 2026 report showing 57% gross margin and a flat fourth-quarter revenue guide. November weight-loss billing data and early Lilly drug sales show whether growth…VKTXViking TherapeuticsLow Viking Therapeutics is more likely to lag the S&P 500 over three months: $960 million in cash funds its obesity Phase 3 trials, but no pivotal efficacy result is scheduled before 2027. The ObesityWeek posters from 15 November 2026 add…BMEABiomea FusionLow Biomea Fusion is more likely to lag the S&P 500 over three months: cash fell to $26.8 million at 30 September 2026 and BMF-650 has no partner; the 16 November 2026 ObesityWeek poster and any financing news settle it.VERULow Veru's case rests on whether its oral drug enobosarm preserves lean mass alongside semaglutide; the PLATEAU 32-week interim, guided to calendar Q1 2027, settles it, while going-concern doubt and an open stock-sale program cap the shares.
Streaming, media & entertainment
5 stocksTracked as of 11 November 2026.
IMAXMedium IMAX Corporation's shares are modestly more likely than not to beat the S&P 500 over three months on a record third quarter and a raised margin target; Dune: Part Three's 18 December 2026 opening and 2027 box-office guidance due early 2027…DISWalt DisneyLow The Walt Disney Company's shares look more likely to trail the S&P 500 than lead it, because a 14.2% three-month gain already prices in parks, streaming and cost-cut gains. The 17 November 2026 fiscal Q4 report shows whether fiscal 2027…NFLXNetflixLow Netflix's shares are more likely to lag the S&P 500 than lead it while members use the service less and its 2026 ad target sits cut; the fourth-quarter report and 2027 outlook, expected around 20 January 2027, decide whether engagement has…AMCAmc Entertainment HoldingsMedium AMC Entertainment's third quarter delivered $109.3 million of free cash flow with no rise in share count, so the shares are rated modestly likely to beat the S&P 500; Thanksgiving attendance and the fourth-quarter report show whether that…IQiQIYILow iQIYI's shares are more likely to lag the S&P 500 over three months: revenue is shrinking, its micro-drama, AI and overseas pivot has no reported revenue line, and the 16 November 2026 third-quarter report shows whether that changes.
Dormant · 26
The research has not tracked these themes in the last 14 days, or has called the story over. Their stocks keep their research.
AI datacenter infrastructure
96 stocksNot tracked as a current theme.
Precision biotech & therapeutics
69 stocksNot tracked as a current theme.
Binary-catalyst biotech
61 stocksNot tracked as a current theme.
Oil, energy & geopolitical
58 stocksThe research has called this story over.
Semi foundry & equipment
29 stocksNot tracked as a current theme.
Networking & optical
28 stocksNot tracked as a current theme.
AI chips & memory
27 stocksNot tracked as a current theme.
Freight & logistics
25 stocksNot tracked as a current theme.
Industrial power & grid
25 stocksNot tracked as a current theme.
Emerging markets
23 stocksNot tracked as a current theme.
GPU cloud & neoclouds
19 stocksNot tracked as a current theme.
Analog semiconductors
18 stocksNot tracked as a current theme.
Housing, homebuilders & proptech
16 stocksNot tracked as a current theme.
Crypto exchanges & financials
15 stocksNot tracked as a current theme.
Space economy
14 stocksNot tracked as a current theme.
EV & autonomous mobility
13 stocksNot tracked as a current theme.
Critical materials & rare earths
12 stocksNot tracked as a current theme.
Nuclear & uranium
11 stocksNot tracked as a current theme.
Bitcoin miners
7 stocksNot tracked as a current theme.
Mega-cap AI platforms
7 stocksNot tracked as a current theme.
Physical AI & robotics
6 stocksNot tracked as a current theme.
Quantum computing
6 stocksNot tracked as a current theme.
Prediction markets & betting
4 stocksNot tracked as a current theme.
Heavily shorted
4 stocksNot tracked as a current theme.
Biofuels & low-carbon fuels
2 stocksNot yet tracked as a current theme.
Cannabis reclassification
2 stocksNot tracked as a current theme.
Common questions
What stock market themes are moving right now?
The 18 themes FrontierPicks currently tracks are led by Consumer brands & retail, Medtech, diagnostics & life-science tools, AI enterprise software, M&A & special situations. A theme is a set of stocks trading on the same story, not a sector label, so one theme often spans several sectors.
How does FrontierPicks decide what counts as a theme?
Each stock's research note is tagged with the stories driving the stock, chosen from a fixed list of 45 named themes. After every close the research picks the themes the market is actually moving on. A theme stays current for 14 days after the research last picked it, unless the research calls the story over: 18 themes are current now, and the rest are listed as dormant.
What is the difference between a theme and a sector?
A sector is a fixed classification of what a company does; a theme is a live claim about why a group of names is moving together now. A single theme routinely spans several sectors, and a name can belong to more than one theme or to none.